Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics

被引:99
作者
Coplan, Paul M. [1 ,2 ]
Kale, Hrishikesh [1 ]
Sandstrom, Lauren [1 ]
Landau, Craig [1 ]
Chilcoat, Howard D. [1 ,3 ]
机构
[1] Purdue Pharma LP, Dept Risk Management & Epidemiol, Stamford, CT USA
[2] Univ Penn, Perelman Sch Med, Dept Clin Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
关键词
opioid abuse; abuse deterrence; poison centers; oxycodone; heroin; patient outcomes; pharmacoepidemiology; MONITORING PROGRAMS; UNITED-STATES; PRESCRIPTION; OPIOIDS; DEATHS; ROUTES; RATES;
D O I
10.1002/pds.3522
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeAbuse and misuse of prescription opioids are serious public health problems. Abuse-deterrent formulations are an intervention to balance risk mitigation with appropriate patient access. This study evaluated the effects of physicochemical barriers to crushing and dissolving on safety outcomes associated with extended-release oxycodone (ERO) tablets (OxyContin) using a national surveillance system of poison centers. Other single-entity (SE) oxycodone tablets and heroin were used as comparators and to assess substitution effects. MethodsThe National Poison Data System covering all US poison centers was used to measure changes in exposures in the year before versus the 2years after introduction of reformulated ERO (7/2009-6/2010 vs 9/2010-9/2012). Outcomes included abuse, therapeutic errors affecting patients, and accidental exposures. ResultsAfter ERO reformulation, abuse exposures decreased 36% for ERO, increased 20% for other SE oxycodone, and increased 42% for heroin. Therapeutic errors affecting patients decreased 20% for ERO and increased 19% for other SE oxycodone. Accidental exposures decreased 39% for ERO, increased 21% for heroin, and remained unchanged for other SE oxycodone. During the study period, other interventions to reduce opioid abuse occurred, for example, educational and prescription monitoring programs. However, these have shown small effects and do not explain a drop for ERO exposures but not for other opioids. ConclusionsAfter ERO reformulation, calls to poison centers involving abuse, therapeutic errors affecting patients, and accidental exposures decreased for ERO, but not for comparator opioids. Abuse-deterrent formulations of opioid analgesics can reduce abuse, but switching to other accessible non abuse-deterrent opioids might occur. (c) 2013 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
引用
收藏
页码:1274 / 1282
页数:9
相关论文
共 35 条
[1]  
[Anonymous], 2013, US OP TREATM CHRON P
[2]  
[Anonymous], 2012, OXYCONTIN FULL PRESC
[3]   Estimated costs of prescription opioid analgesic abuse in the United States in 2001 - A societal perspective [J].
Birnbaum, Howard G. ;
White, Alan G. ;
Reynolds, Jennifer L. ;
Greenberg, Paul E. ;
Zhang, Mingliang ;
Vallow, Sue ;
Schein, Jeff R. ;
Katz, Nathaniel P. .
CLINICAL JOURNAL OF PAIN, 2006, 22 (08) :667-676
[4]   2011 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report [J].
Bronstein, Alvin C. ;
Spyker, Daniel A. ;
Cantilena, Louis R., Jr. ;
Rumack, Barry H. ;
Dart, Richard C. .
CLINICAL TOXICOLOGY, 2012, 50 (10) :911-1164
[5]   Abuse Rates and Routes of Administration of Reformulated Extended-Release Oxycodone: Initial Findings From a Sentinel Surveillance Sample of Individuals Assessed for Substance Abuse Treatment [J].
Butler, Stephen F. ;
Cassidy, Theresa A. ;
Chilcoat, Howard ;
Black, Ryan A. ;
Landau, Craig ;
Budman, Simon H. ;
Coplan, Paul M. .
JOURNAL OF PAIN, 2013, 14 (04) :351-358
[6]   Abuse risks and routes of administration of different prescription opioid compounds and formulations [J].
Butler, Stephen F. ;
Black, Ryan A. ;
Cassidy, Theresa A. ;
Dailey, Taryn M. ;
Budman, Simon H. .
HARM REDUCTION JOURNAL, 2011, 8
[7]  
Butler Stephen F, 2010, J Opioid Manag, V6, P239
[8]   National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse [J].
Butler, Stephen F. ;
Budman, Simon H. ;
Licari, Andrea ;
Cassidy, Theresa A. ;
Lioy, Katherine ;
Dickinson, James ;
Brownstein, John S. ;
Benneyan, James C. ;
Green, Traci Craig ;
Katz, Nathaniel .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (12) :1142-1154
[9]  
Centers for Disease Control and Prevention (CDC), 2005, CDC FACT SHEET US NA
[10]   Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain [J].
Chou, Roger ;
Fanciullo, Gilbert J. ;
Fine, Perry G. ;
Adler, Jeremy A. ;
Ballantyne, Jane C. ;
Davies, Pamela ;
Donovan, Marilee I. ;
Fishbain, David A. ;
Foley, Kathy M. ;
Fudin, Jeffrey ;
Gilson, Aaron M. ;
Kelter, Alexander ;
Mauskop, Alexander ;
O'Connor, Patrick G. ;
Passik, Steven D. ;
Pasternak, Gavril W. ;
Portenoy, Russell K. ;
Rich, Ben A. ;
Roberts, Richard G. ;
Todd, Knox H. ;
Miaskowski, Christine .
JOURNAL OF PAIN, 2009, 10 (02) :113-130